Abstract：
UNASSIGNED: The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti-PD-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT.
UNASSIGNED: This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles.
UNASSIGNED: During a median follow-up of 11.23 months (range, 3.07-34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The two-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively.
UNASSIGNED: Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.
UNASSIGNED: This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child Pugh class A or B, and had at least one measurable lesion. The overall survival (OS), progression-free survival (PFS), objective response rates, and disease control rates were analyzed to assess efficacy. Treatment-related adverse events were analyzed to assess safety profiles.
UNASSIGNED: During a median follow-up of 11.23 months (range, 3.07-34.37 months), the median OS was greater than 24 months, and median PFS was 12.53 months. The two-year OS rate was 54.9%. The objective response rate and disease control rate were 69.8% (74/106) and 84.0% (89/106), respectively; 20.8% (22/106) of the patients experienced grade 3/4 treatment-related adverse events and no treatment-related deaths occurred. The conversion rate to liver resection was 31.1% (33/106), with manageable postoperative complications. The median OS was not reached in the surgery group, but was 19.08 months in the non-surgery group. The median PFS in the surgery and non-surgery groups were 20.50 and 9.00 months, respectively.
UNASSIGNED: Triple therapy showed promising survival benefits and high response rates in patients with HCC and PVTT, with manageable adverse effects.
摘要：
■肝细胞癌（HCC）和门静脉癌栓（PVTT）患者的预后极差，全身治疗是目前的主流治疗方法。本研究旨在评估lenvatinib联合抗PD-1抗体和经导管动脉化疗栓塞（三联疗法）在HCC和PVTT患者中的疗效和安全性。
■这项回顾性多中心研究包括接受三联疗法的HCC和PVTT患者，年龄在18到75岁之间，分类为ChildPughA级或B级，至少有一个可测量的病变。总生存期（OS），无进展生存期（PFS），客观反应率，和疾病控制率进行分析以评估疗效。分析治疗相关的不良事件以评估安全性。
■在11.23个月的中位随访期间（范围，3.07-34.37个月)，中位OS大于24个月，中位PFS为12.53个月.两年OS率为54.9%。客观有效率和疾病控制率分别为69.8%(74/106)和84.0%(89/106),20.8%(22/106)的患者出现3/4级治疗相关不良事件,无治疗相关死亡.肝切除的转化率为31.1％（33/106），术后并发症可控。手术组未达到中位OS，但非手术组为19.08个月.手术组和非手术组的中位PFS分别为20.50和9.00个月,分别。
■三联疗法在HCC和PVTT患者中显示出有希望的生存益处和高反应率，具有可控的不良反应。
■这项回顾性多中心研究包括接受三联疗法的HCC和PVTT患者，年龄在18到75岁之间，分类为ChildPughA级或B级，至少有一个可测量的病变。总生存期（OS），无进展生存期（PFS），客观反应率，和疾病控制率进行分析以评估疗效。分析治疗相关的不良事件以评估安全性。
■在11.23个月的中位随访期间（范围，3.07-34.37个月)，中位OS大于24个月，中位PFS为12.53个月.两年OS率为54.9%。客观有效率和疾病控制率分别为69.8%(74/106)和84.0%(89/106),20.8%(22/106)的患者出现3/4级治疗相关不良事件,无治疗相关死亡.肝切除的转化率为31.1％（33/106），术后并发症可控。手术组未达到中位OS，但非手术组为19.08个月.手术组和非手术组的中位PFS分别为20.50和9.00个月,分别。
■三联疗法在HCC和PVTT患者中显示出有希望的生存益处和高反应率，具有可控的不良反应。
